Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib combined with immunochemotherapy for newly treated high-risk diffuse large B-cell lymphoma
ChiCTR2100053805Phase 2Recruiting
- Sponsor
- Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of orelabrutinib in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine. Primary endpoint: Complete remission rate. Started Dec 2021; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2100053805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053805.